Moderna's mRNA Cancer Vaccine Shows Promising Results in Melanoma Trial

Moderna's personalized mRNA cancer vaccine, intisomeran, has demonstrated significant success in a Phase 3 trial, offering new hope in the fight against melanoma. Developed in collaboration with Merck, the vaccine aims to prevent the recurrence or spread of the most serious form of skin cancer after surgical removal.

The investigational vaccine, intisomeran, is tailored to each patient's unique tumor. It is administered concurrently with Merck's Keytruda, a widely used cancer immunotherapy. The trial, involving over a thousand patients, compared a group receiving both intisomeran and Keytruda against a control group receiving only Keytruda.

Moderna hailed the results as a "major milestone" in cancer research. Previous studies indicated that the combination therapy could reduce the risk of cancer recurrence or death by nearly half compared to Keytruda alone. The mRNA technology, familiar from COVID-19 vaccines, is here repurposed to train the immune system to recognize and attack cancer cells.

However, experts caution that detailed results are still forthcoming. The companies have yet to release specific data on the magnitude of the difference between the treatment groups or whether the vaccine has improved patients' overall survival rates. Further findings are expected to be presented at a medical conference later this year. Moderna and Merck are also exploring the vaccine's potential against other cancers, including lung, bladder, and kidney cancers.

“

Major milestone